CTRI/2022/08/044836已完成未知
A Mono-center, matched-Control Study to Investigate the Skin Biofilm Profile on Asian Acne Volunteers Compared to Healthy Volunteers
Singapore Centre for Environmental Life Sciences Engineering0 个研究点目标入组 12 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Healthy non-pregnant female volunteer from 18 to 25 years old.
- •2.Asian population with skin type II-V per Fitzpatrick classification.
- •3.Female of childbearing potential who is not sexually active, or who is using an effective contraceptive method for at least one month before the beginning of the study and throughout the study.
- •4.Female of childbearing potential willing to undergo urine pregnancy test.
- •5.For Acne subjects:
- •a. Acne grading (IGA:3 moderate) on face and back declaring persistent acne since the adolescence.
- •b. Subjects showing the facial acne at least 15 inflammatory lesions (papules and pustules) and 25 non-inflammatory lesions (blackheads and whiteheads) on the face, and the same count criteria on the upper back for acne volunteers.
- •6.For Healthy subject: Healthy volunteer without acne on face or back in her life.
- •7.Subject informed about the study objectives and procedures, and able to understand them.
- •8.Subject willing to give written informed consent and willing to comply with the study protocol and schedule.
- •9.Subject willing to shower only with water 2 days before, and not shower 1 day before and not apply any topical hygiene/personal care products on face and body. On the day of evaluation visit, subject willing not to shower and wash their face and not apply topical hygiene/personal care products on face and body. Subject willing to wear loose fitting soft cotton clothes provided by site.
- •10.Subject willing to have a small 3 mm skin biopsy collected from the back.
- •11.Agreeable to take a COVID-19 RT-PCR test less than 48 hours before evaluation visit.
排除标准
- •1.Nursing, pregnant, or is planning to be pregnant according to subject self-report during the study.
- •2.Having a history of skin cancer within the past 5 years.
- •3.Menopausal female (with absence of menstruations for less than one year) or post-menopausal female (with absence of menstruations for more than one year).
- •4.Subject with BMI > 30.
- •5.History of allergies, hypersensitivity or any serious reactions to any cosmetic products, and any serious reaction to local anaesthesia, local antibiotic & antiseptic, history of healing defects (hypertrophy, keloid, etc).
- •6.Subject with any disease state or dermatological disorders affecting the investigational areas (presence of burns, wounds or irritation, naevi, vitiligo, active/history of psoriasis, moles, active eczema, scars, tattoos, excessive hair etc.) that might impair evaluations or increase the health risk to the subject by participating in the opinion of the Investigator.
- •7.Any concomitant medical condition that may interfere with the study conduct in the opinion of the investigator.
- •8.Reporting any UV exposure in the past month or planning UV exposure of the face (sunlight or sunbeds) throughout the study.
- •9.Dermatological or aesthetic procedures on the face and back (deep skin cleansing, dermabrasion, peeling, light-therapy, laser, etc.) within the last 3 months before the screening visit and intending to receive them during the study period.
- •10.Having used within the 8 past weeks for more than 3 consecutive days any systemic or topical drugs related to antibiotics, anti-inflammatory drug, corticoids, retinoid (topical) or any anti-acne or anti-seborrheic products or having planned to use these treatments during the study.
- •11.Having used oral Isotretinoin treatment in adolescence or adult age.
- •12.Having used within the last month before inclusion any depigmenting / whitening or pro-pigmenting (incl. self-tanning) topical treatments or having planned to use these treatments during the study on the face.
- •13.Having used, within the past 6 months, any physical treatment including laser or phototherapy (PUVA, IPL, PDT), Botox or fillers like hyaluronic acid on the investigational sites or having planned to use these treatments during the study.
- •14.Having used any cosmetic routines such as scrub, deep cleansing of the skin, to the face within past 4 weeks and intended to perform them during the study period.
- •15.Having used cosmetics for more than 5 consecutive days within the past 7 days related to alpha hydroxyl-acids, vitamin C, hyaluronic acids, any alcohol-based products like toners, facial astringents etc.) or having planned to use these treatments during the study.
- •16.Having changed their face skin care products and their cosmetic washing habits for the area to be treated (shower gel, shampoo…) within the past 10 days before the screening visit.
- •17.Having practice any intensive physical activity, sports practice ( > 10 hours a week), hammam, sauna or swimming-pool (nautical sports) within the past week before the screening visit or planned during the study.
- •18.Following a strictly vegetarian, vegan diet or cure of mineral or vitamin supplements before the beginning of the study or planned during the study.
- •19.Deprivation of freedom by administrative or legal decision or who are under guardianship.
- •20.Having participated within the 30 days before scr
研究者
相似试验
招募中
Unknown
A trial to check the growth of microorganism on skin of subjects with acne as compared non acne subjectsCTRI/2024/02/062767SCELSE
招募中
不适用
Verification of the effect of a Trunk Solution Improves Posture for patients with Parkinson's Disease of Forward Bending Posture.s DiseaseParkinson's DiseaseJPRN-UMIN000049433agasaki Kita Hospital40
进行中（未招募）
1 期
A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC) - PRESTEUCTR2008-002667-13-DEniversity Clinic of Heidelberg40
已完成
不适用
A single-center, single-blind study to investigate skin response to sub-therapeutic doses of taspoglutide in GLP-1 analogue naive healthy volunteersdiabetesNL-OMON34382Hoffmann-La Roche6
已完成
不适用
A single center, randomized study investigating the safety, tolerability, and pharmacokinetics of AZ-009 (Staccato apomorphine) in healthy volunteers and the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZ-009 in subjects with established Parkinson*s Disease.PDParkinson's diseaseParkinson's DiseaseNL-OMON48728Alexza Pharmaceuticals Inc.56